# Metabolism-corrected propofol exposure intensity and long-term intelligence quotient in pediatric febrile infection-related epilepsy syndrome: a retrospective cohort study

**Authors:** Rongrong Li, Lin Yan, Xiaoming Wu, Baohua Wang, Fengzhan Chen, Xiaoyan Wang, Feng Gao, Jianhang Chen

PMC · DOI: 10.3389/fmed.2026.1747795 · Frontiers in Medicine · 2026-02-12

## TL;DR

This study finds that high propofol exposure in children with a severe epilepsy syndrome is linked to long-term cognitive decline and intellectual disability.

## Contribution

The study introduces a new metric, metabolism-corrected propofol exposure intensity, to assess dose-dependent cognitive outcomes in pediatric FIRES patients.

## Key findings

- Each 100 mg/kg increase in dose residuals was associated with a 0.41-point decrease in Full-Scale Intelligence Quotient.
- Above 2,000 mg/kg exposure, cognitive decline accelerated significantly.
- High propofol exposure was linked to a 79% rate of intellectual disability compared to 44% in the low exposure group.

## Abstract

Febrile infection-related epilepsy syndrome (FIRES) often requires prolonged gamma-aminobutyric acid (GABA)-ergic anesthesia for super-refractory status epilepticus; however, the neurocognitive impact of propofol, independent of disease severity, remains unclear. This study aimed to distinguish practice-driven propofol administration from illness severity–driven necessity and to evaluate the dose-dependent association of propofol with long-term cognitive outcomes in children.

This retrospective cohort study included 74 FIRES survivors (median age: 7.2 years) who were admitted from 2014 to 2022. We developed the metabolism-corrected propofol exposure intensity (MC-PEI) metric, which standardizes cumulative propofol dose (mg/kg) to ideal body weight and adjusts for organ dysfunction. A generalized additive model linked MC-PEI to illness severity markers to derive dose residuals (DR), reflecting variation in clinical practice.

The median MC-PEI was 2,180 mg/kg. After applying inverse probability of treatment weighting (IPTW), each 100 mg/kg increase in DR was independently associated with a decrease of 0.41 points in the Full-Scale Intelligence Quotient (FSIQ) (p = 0.003). The high DR tertile had a mean FSIQ score of 63.7, which is below the intellectual disability threshold (<70). A significant inflection point was observed at MC-PEI = 2,000 mg/kg: above this level, the FSIQ declined by 0.55 points per 100 mg/kg (p < 0.001). High DR was associated with a 79% rate of intellectual disability, compared to 44% in the low DR group (p = 0.009). Additionally, the rate of school re-entry dropped to 21%.

Practice-driven propofol exposure significantly impairs long-term cognition in a dose-dependent manner in FIRES, with accelerated neurotoxicity beyond 2,000 mg/kg. This threshold should prompt a mandatory multidisciplinary review and consideration of alternative treatment options.

## Linked entities

- **Chemicals:** propofol (PubChem CID 4943)
- **Diseases:** febrile infection-related epilepsy syndrome (MONDO:0015584), intellectual disability (MONDO:0001071)

## Full-text entities

- **Genes:** SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CYP2B6 (cytochrome P450 family 2 subfamily B member 6) [NCBI Gene 1555] {aka CPB6, CYP2B, CYP2B7, CYPIIB6, EFVM, IIB1}
- **Diseases:** toxicity (MESH:D064420), P (MESH:D002972), neurocognitive harm (MESH:D019965), FIRES (MESH:D007239), epilepsy syndrome (MESH:D000073376), deaths (MESH:D003643), brain injury (MESH:D001930), Intellectual disability (MESH:D008607), epileptic encephalopathy (MESH:D001927), neuro (MESH:C536203), epilepsy (MESH:D004827), cognitive decrement (MESH:D003072), MOD (MESH:C564833), neurodevelopmental disorders (MESH:D002658), Liver dysfunction (MESH:D017093), dysfunction (MESH:D006331), loss of schooling (MESH:D010698), Renal dysfunction (MESH:D007674), DR (MESH:D018365), neuroinflammation (MESH:D000090862), neurotoxic (MESH:D020258), ID (MESH:C537985), mitochondrial dysfunction (MESH:D028361), inflammation (MESH:D007249), neurodevelopmental injury (MESH:D014947), neurodegeneration (MESH:D019636), epilepticus (MESH:D013226), seizure (MESH:D012640), IQ deficit (MESH:D009461), refractory epilepsy (MESH:D000069279), febrile (MESH:D000071072), obese (MESH:D009765), organ dysfunction (MESH:D009102)
- **Chemicals:** MC (MESH:C061001), rocuronium (MESH:D000077123), FSIQ (-), barbiturates (MESH:D001463), creatinine (MESH:D003404), reactive oxygen species (MESH:D017382), bilirubin (MESH:D001663), lactate (MESH:D019344), midazolam (MESH:D008874), GABA (MESH:D005680), Propofol (MESH:D015742), fentanyl (MESH:D005283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935992/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12935992/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935992/full.md

---
Source: https://tomesphere.com/paper/PMC12935992